Elekta presents long-term strategy and financial scenario at capital markets day

STOCKHOLM, September 27, 2018 – At its Capital Markets Day in Stockholm today, Elekta (EKTA-B.ST) presented the company’s long-term strategy and a new financial scenario for the period until fiscal year 2022/23. This includes a net sales compound annual growth rate (CAGR) of 8-10 percent, based on constant exchange rates, combined with EBITA margin improvement of up to 200 basis points towards the end of the period, from the 20 percent reported on a rolling 12-month basis. The company also reiterated its outlook for fiscal year 2018/19.

Richard Hausmann, Elekta’s President and CEO, said that over the last few years Elekta has built a solid foundation for further growth. “We have improved our margin and cash flow and have returned to high growth. We are now in a good position to realize our vision. The future of our industry is in precision radiation medicine, including diagnostic quality imaging at the point of treatment, real-time adaptive treatment planning, data-driven personalization and intelligent automation. We believe that these will significantly improve current treatments, enable better patient outcomes and increase operational efficiency for the clinic. Elekta Unity is an important step on this journey and we expect it to become the standard of care within precision radiation medicine and see an addressable market of 3,000 to 4,000 systems.”

He also spoke of the importance of treatment for all – making high quality radiotherapy available and accessible to every cancer patient around the world. “We want to give people everywhere the same chance to beat cancer and have launched initiatives specifically focused on developing solutions for emerging economies.”

Richard Hausmann concluded that Elekta’s ambition is to be the thought leader in the radiation medicine market: “We have been the innovation frontrunner for decades and will continue to lead this industry.”

Elekta’s previous long-term financial ambitions have been under review, as stated in Elekta’s annual report 2017/18, and are superseded by the new financial scenario communicated today.

This is information that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 13:00 CET on September 27, 2018. (REGMAR)

# # #

This is information that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 13:00 CET on September 27, 2018. (REGMAR)

About Elekta

Elekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. Our advanced, effective solutions are created in collaboration with customers, and more than 6,000 hospitals worldwide rely on Elekta technology. Our treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows. Elekta employs 3,700 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm. www.elekta.com.

Press Releases

Downloads

PDF Version

For further information, please contact

Oskar Bosson, EVP Corporate Communications and Investor Relations
Tel: +46 70 410 7180,
E-mail: oskar.bosson@elekta.com
Time zone: CET: Central European Time

Johan Andersson, Director Investor Relations
Tel: +46 70 210 0451,
E-mail: johan.andersson@elekta.com